Home blood test for monitoring harmful metabolic levels
Official title: Whole Blood Point of Care Metabolic Measurement - SB1
Funded at Sequitur Health Corp. · NIH-11193960 · Data updated 2026-11-12
A small, at‑home device that measures a dangerous blood metabolite from one drop for people with metabolic disorders.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sequitur Health Corp. NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,000,001 |
| NIH project number | 5SB1HD116629-02 |
| Project ID | NIH-11193960 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with inherited metabolic disorders that cause dangerous buildup of this metabolite (for example urea cycle disorders or certain organic acidemias) who monitor blood levels and can perform fingerstick testing.
✕Less likely to help
People without those specific metabolic disorders, those who do not perform fingerstick blood sampling, or those needing other laboratory tests are unlikely to benefit directly from this device.
What this research studies
This project aims to finish developing a portable device that can measure the metabolite that triggers metabolic crises (for example, high ammonia) from a single drop of whole blood. The company previously demonstrated accurate measurements in Phase II work and now plans software refinement, scaled hardware manufacturing, and steps needed for regulatory approval and market readiness. The work focuses on late‑stage engineering and commercialization activities rather than basic lab research. If pilots are run, they would likely involve small user tests or clinical pilots to confirm real‑world performance.
Why it matters
Potential benefit: If successful, the device could let patients and caregivers check metabolite levels at home and take action earlier to prevent metabolic crises.
How similar studies have gone: Earlier Phase II and NSF–supported work reported accurate single‑drop measurements, so this effort builds on promising prior technical results.
Where this research is happening
-
Sequitur Health Corp.
Scottsdale, United States Active
Researchers
- Principal investigator: Thomas, Marylaura Lind — Sequitur Health Corp.
- Study coordinator: Thomas, Marylaura Lind
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.